Michael Spence, MD
Physical Medicine & Rehabilitation · Highland, INNPI 1558388157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $611 and has fallen 97.0% since, to $18 in 2025.
Across 124 payments — averaging $13.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$336
- Scilex Pharmaceuticals Inc.$292
- AbbVie$240
- Amgen$173
- Collegium Pharmaceutical, Inc.$123
- Biodelivery Sciences International, Inc.$107
- plus $415 from 15 others
What the payments were for
- Food & beverage$1,686100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $336 |
| Scilex Pharmaceuticals Inc. | 27 | $292 |
| AbbVie(2 entities) | 13 | $240 |
| Amgen | 10 | $173 |
| Collegium Pharmaceutical, Inc. | 9 | $123 |
| Biodelivery Sciences International, Inc. | 7 | $107 |
| Arbor Pharmaceuticals, Inc. | 8 | $107 |
| Zyla Life Sciences, Inc. | 5 | $66 |
| IBSA Pharma Inc. | 2 | $33 |
| Shionogi Inc | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| MDD US Operations, LLC | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Electronic Waveform Lab, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Pernix Therapeutics Holdings, Inc. | 1 | $11 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
| Boston Scientific | 1 | $11 |
How this compares
$1,686 in reported general payments places this provider in the 75th percentile of 140 physical medicine & rehabilitation providers in Indiana.
See all physical medicine & rehabilitation providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 785 | $28,095 |
| ZtlidoLidocaine | 14 | $14,945 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 272 | $11,012 |
| OxycontinOxycodone Hcl | 13 | $6,028 |
| BelbucaBuprenorphine Hcl | 12 | $5,813 |
| Buprenorphine | 16 | $4,691 |
| Lidocaine | 26 | $2,462 |
| Gabapentin | 176 | $2,198 |
| Oxycodone Hcl | 73 | $1,957 |
| Celecoxib | 25 | $1,840 |
| Pregabalin | 59 | $1,671 |
| Morphine Sulfate ErMorphine Sulfate | 47 | $1,230 |
| Diclofenac Sodium | 25 | $1,016 |
| Tramadol Hcl | 78 | $916 |
| Tizanidine Hcl | 120 | $702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Ztlido | $292 | $14,94514 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $123 | $5,81312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 140 physical medicine & rehabilitation providers in Indiana.
Other physical medicine & rehabilitation in Highland
- Christina WalzFort Wayne$503K
- Shashank DaveIndianapolis$198K
- Sayed WaheziFort Wayne$161K
- Andrew DavissonNew Castle$74K
- Sachin MehtaIndianapolis$60K
- David StenslandFort Wayne$24K
- Scott TaylorNew Castle$18K
- Jeffrey BeckTerre Haute$10K
- Daniel RothFort Wayne$10K
- Anthony MimmsIndianapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.